Comparative Pharmacology
Head-to-head clinical analysis: CLOCORTOLONE PIVALATE versus FLURANDRENOLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOCORTOLONE PIVALATE versus FLURANDRENOLIDE.
CLOCORTOLONE PIVALATE vs FLURANDRENOLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clocortolone pivalate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical: Apply a thin film to affected area once or twice daily. Not for ophthalmic use. Maximum duration of 2 weeks per course.
Apply 0.025% to 0.05% cream or ointment topically to affected area twice daily.
None Documented
None Documented
Clinical Note
moderateFlurandrenolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin."
Clinical Note
moderateFlurandrenolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rosoxacin."
Clinical Note
moderateFlurandrenolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 2.5 hours (range 1-4 hours), reflecting rapid clearance; clinical duration exceeds half-life due to tissue binding.
Terminal elimination half-life approximately 18–36 hours; clinical context: prolonged with hepatic impairment; supports once-daily or twice-daily topical dosing.
Primarily renal (approximately 80%) as glucuronide and sulfate conjugates; minor biliary/fecal excretion (20%).
Renal (<1% unchanged), biliary/fecal (major route, as metabolites); <1% excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
Flurandrenolide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Trovafloxacin."